The Patent Finder

Glycomimetics, Inc.

24 patents currently held · Updated Nov 21, 2026
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 4 name spellings.

8
Ending by 2030
Mar 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 25, 2027
    The maintenance fee for Methods for treating acute myeloid leukemia and related conditions (US 11,707,474) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
  • 2 fees due Feb 1 to 18, 2027 · next Feb 1
  • 1 fee due Apr 10, 2027
    The maintenance fee for Highly potent multimeric e-selectin antagonists (US 11,780,873) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
  • 1 fee due Jun 19, 2027
    The maintenance fee for Heterobifunctional inhibitors of E-selectin and galectin-3 (US 11,845,771) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
  • 3 fees due Jul 7 to 23, 2027 · next Jul 7

Which patents, and when each one lapses · Pro

Recent changes

  • 2 terms have ended since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,517,980Glycomimetric inhibitors of the PA-IL lectin, PA-IIL lectin or both the lectins from Pseudomonas
In force
 · USPTO record
In forceUSPTO record
US 8,258,290Glycomimetic inhibitors of the PA-IL lectin, PA-IIL lectin or both the lectins from pseudomonas
In force
 · USPTO record
In forceUSPTO record
US 8,361,975Compounds and methods for treatment of sickle cell or complications associated therewith
In force
 · USPTO record
In forceUSPTO record
US RE44,778Heterobifunctional pan-selectin inhibitors
In force
 · USPTO record
In forceUSPTO record
US 9,534,009Pan-selectin inhibitor with enhanced pharmacokinetic activity
In force
 · USPTO record
In forceUSPTO record
US 8,039,442Compounds and methods for treatment of sickle cell disease or complications associated therewith
In force
 · USPTO record
In forceUSPTO record
US 7,964,569Glycomimetic replacements for hexoses and N-acetyl hexosamines
In force
 · USPTO record
In forceUSPTO record
US 8,026,222Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines
In force
 · USPTO record
In forceUSPTO record
US 8,921,328E-Selectin Antagonists
In force
 · High confidence
In forceHigh confidence
US 8,895,510Pan-selectin inhibitor with enhanced pharmacokinetic activity
In force
 · USPTO record
In forceUSPTO record
10 of 24 patents shown.
Pro members see all 24.
Pro members: see all 24 patents
Also on record, not counted in the 24: 2 patents in force now held by others · 11 lapsed for an unpaid fee · 13 ended at full term · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending · 4 abandoned · 42 no status recorded

Showing 1 to 10 of 49, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
18/527,321Dec 3, 2023No status recorded
18/503,499Nov 7, 2023No status recorded
18/354,837Jul 19, 2023No status recorded
18/330,757Jun 7, 2023No status recorded
18/327,429Methods of Mobilizing Marrow Infiltrating Lymphocytes and Uses ThereofJun 1, 2023Abandoned
18/698,081Sep 30, 2022No status recorded
18/291,884Aug 2, 2022No status recorded
17/876,213Combination of T-Cell Checkpoint Inhibitors with Inhibitors of E-Selectin or CXCR4, or with Heterobifunctional Inhibitors of Both E-Selectin and CXCR4Jul 28, 2022Abandoned
18/562,804May 13, 2022No status recorded
18/560,441GALECTIN-3 Inhibiting C-GlycosidesMay 13, 2022Abandoned
10 of 49 applications shown.
Pro members see all 49 published applications.
Pro members: see all 49 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited